Joseph Lobacki
Direttore/Membro del Consiglio presso SUTRO BIOPHARMA, INC.
Patrimonio netto: - $ in data 31/05/2024
Profilo
Joseph M.
Lobacki currently works at Sutro Biopharma, Inc., as Independent Director from 2017.
Mr. Lobacki also formerly worked at Artax Biopharma, Inc., as President, Chief Executive Officer & Director from 2020 to 2024, Celator Pharmaceuticals, Inc., as Independent Director from 2013 to 2016, SangStat Medical Corp., as Vice President-North American Marketing, Idera Pharmaceuticals, Inc., as General Manager-Oncology Business from 2012 to 2014, Cell Pathways, Inc., as Vice President-Operations, Genzyme Corp., as Senior VP, General Manager-Transplant & Oncology from 2003 to 2011, Medivation LLC (California), as Chief Commercial Officer & Council Member from 2014 to 2016, Amgen Rockville, Inc., as Chief Commercial Officer & Senior Vice President from 2011 to 2014, Verastem, Inc., as Chief Commercial Officer & Executive VP from 2018 to 2019, Finch Research & Development LLC, as Chief Operating Officer from 2016 to 2017, Finch Therapeutics Group, Inc., as Chief Operating Officer from 2013 to 2017, and Micromet Inc., as Chief Commercial Officer & Senior Vice President.
Mr. Lobacki received his undergraduate degree in 1980 from Boston College and undergraduate degree in 1983 from Massachusetts College of Pharmacy & Health Science.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
SUTRO BIOPHARMA, INC.
-.--% | 06/06/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Joseph Lobacki
| Società | Posizione | Inizio |
|---|---|---|
| SUTRO BIOPHARMA, INC. | Direttore/Membro del Consiglio | 01/02/2017 |
Precedenti posizioni note di Joseph Lobacki
| Società | Posizione | Fine |
|---|---|---|
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Amministratore Delegato | 04/01/2024 |
| VERASTEM, INC. | Corporate Officer/Principal | 01/01/2019 |
Finch Research & Development LLC
 Finch Research & Development LLC Pharmaceuticals: MajorHealth Technology Part of Finch Therapeutics Group, Inc., Finch Research & Development LLC provides biopharmaceutical services. The company is based in Cambridge, MA. Finch Research & Development was acquired by Finch Therapeutics, Inc. on October 23, 2017. | Direttore operativo | 01/12/2017 |
| FINCH THERAPEUTICS GROUP, INC. | Direttore operativo | 01/12/2017 |
| MEDIVATION INC | Corporate Officer/Principal | 01/10/2016 |
Formazione di Joseph Lobacki
| Boston College | Undergraduate Degree |
| Massachusetts College of Pharmacy & Health Science | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| SUTRO BIOPHARMA, INC. | Health Technology |
| VERASTEM, INC. | Health Technology |
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Aziende private | 10 |
|---|---|
| SangStat Medical Corp. | Health Technology |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Cell Pathways, Inc.
 Cell Pathways, Inc. Pharmaceuticals: OtherHealth Technology Cell Pathways, Inc. develops and commercializes drugs for the prevention and treatment of cancer | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Celator Pharmaceuticals, Inc.
 Celator Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Celator Pharmaceuticals, Inc. engages in the research and development of biopharmaceutical products. The company was founded by Lawrence David Mayer, and Marcel B. Bally in 1999 and is headquartered in Ewing, NJ. | Health Technology |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
Finch Research & Development LLC
Finch Research & Development LLC Pharmaceuticals: MajorHealth Technology Part of Finch Therapeutics Group, Inc., Finch Research & Development LLC provides biopharmaceutical services. The company is based in Cambridge, MA. Finch Research & Development was acquired by Finch Therapeutics, Inc. on October 23, 2017. | Health Technology |
| Micromet Inc. |
- Borsa valori
- Insiders
- Joseph Lobacki
